November 27, 2025
Recce Pharmaceuticals Ltd.
ISIN: AU000000RCE5
Hong Kong Patent Granted for RECCE® Anti-Infectives
Sydney Australia, 27 November 2025: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to announce the...
Read more >>Positive Efficacy Data of Inhaled RECCE® 327 in Hospital/Ventilator-Acquired Pneumonia (HAP/VAP) in Mice Models
Highlights: - RECCE® 327 (R327) demonstrated significant antibacterial activity against multidrug-resistant Acinetobacter baumannii (A. baumannii), one of the most challenging and antibiotic-resistant bacteria associated with hospital-acquired infections - Preliminary reductions in key pro-inflammatory indicators were observed in R327-treated groups - Nebulised inhaled R327 was well tolerated and displayed...
Read more >